[HIV-1 env glycoprotein gp120 and gp160 expressed in vaccinia virus system and their antigenicity analysis]
- PMID: 10453506
[HIV-1 env glycoprotein gp120 and gp160 expressed in vaccinia virus system and their antigenicity analysis]
Abstract
Human immunodeficiency virus type 1 (HIV-1) is the principal causative agent of AIDS that is an important concerns to human being health. The most important antigen of HIV-1 is its envelope glycoprotein gp160 (gp120 + gp41). By means of genetic engineering techniques, HIV-1 gp120 and gp160 were constructed and expressed in the recombinant vaccinia virus system under the control of bacteriophage T7 promoter or vaccinia virus p7.5 promoter. The results showed that the recombinant gp120 and gp160 expressed in this system exist in the form as glycoproteins, resuming the native epitope conformation of the viruses from which they were derived. These recombinant gp120 and gp160 could be recognized by the virus-specific neutralizing monoclonal antibodies. The findings suggested that the recombinant HIV-1 gp120 and gp160 could be used as a candidate recombinant protein vaccines.
Similar articles
-
Mapping of the human immunodeficiency virus type 2 envelope glycoprotein CD4 binding region and fusion domain with truncated proteins expressed by recombinant vaccinia viruses.Virology. 1993 May;194(1):37-43. doi: 10.1006/viro.1993.1232. Virology. 1993. PMID: 8480426
-
Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.Virology. 1996 Apr 1;218(1):224-31. doi: 10.1006/viro.1996.0182. Virology. 1996. PMID: 8615025
-
Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.Clin Immunol. 2006 Apr;119(1):32-7. doi: 10.1016/j.clim.2005.12.007. Epub 2006 Feb 2. Clin Immunol. 2006. PMID: 16458074
-
Functions of HIV envelope glycans.Trends Biochem Sci. 1994 Feb;19(2):65-70. doi: 10.1016/0968-0004(94)90034-5. Trends Biochem Sci. 1994. PMID: 8160267 Review.
-
[Analysis of the principal neutralization site of HIV-1 and vaccine research].Tanpakushitsu Kakusan Koso. 1997 May;42(7 Suppl):1201-8. Tanpakushitsu Kakusan Koso. 1997. PMID: 9170954 Review. Japanese. No abstract available.